Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion
M Filippi, MP Amato, D Centonze, P Gallo… - Journal of …, 2022 - Springer
Multiple sclerosis (MS) is a chronic and progressive neurological disease that is
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
characterized by neuroinflammation, demyelination and neurodegeneration occurring from …
Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting
Increasing numbers of drugs are being developed for the treatment of multiple sclerosis
(MS). Measurement of relevant outcomes is key for assessing the efficacy of new drugs in …
(MS). Measurement of relevant outcomes is key for assessing the efficacy of new drugs in …
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain
Multiple sclerosis is a chronic inflammatory disease with primary demyelination and
neurodegeneration in the central nervous system. In our study we analysed demyelination …
neurodegeneration in the central nervous system. In our study we analysed demyelination …
Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant
Abstract See Chard and Miller (doi: 10.1093/brain/awv354) for a scientific commentary on
this article. Grey matter atrophy is common in multiple sclerosis. However, in contrast with …
this article. Grey matter atrophy is common in multiple sclerosis. However, in contrast with …
Longitudinal multiple sclerosis lesion segmentation: resource and challenge
In conjunction with the ISBI 2015 conference, we organized a longitudinal lesion
segmentation challenge providing training and test data to registered participants. The …
segmentation challenge providing training and test data to registered participants. The …
In vivo quantification of demyelination and recovery using compartment-specific diffusion MRI metrics validated by electron microscopy
There is a need for accurate quantitative non-invasive biomarkers to monitor myelin
pathology in vivo and distinguish myelin changes from other pathological features including …
pathology in vivo and distinguish myelin changes from other pathological features including …
MRI in the diagnosis and monitoring of multiple sclerosis: an update
MP Wattjes, MD Steenwijk, M Stangel - Clinical neuroradiology, 2015 - Springer
Magnetic resonance imaging (MRI) is the most powerful tool for the early (differential)
diagnosis of multiple sclerosis (MS) and has been part of the International Panel criteria …
diagnosis of multiple sclerosis (MS) and has been part of the International Panel criteria …
Prognostic value of single-subject grey matter networks in early multiple sclerosis
The identification of prognostic markers in early multiple sclerosis (MS) is challenging and
requires reliable measures that robustly predict future disease trajectories. Ideally, such …
requires reliable measures that robustly predict future disease trajectories. Ideally, such …
Biomarkers of multiple sclerosis: current findings
VK Harris, JF Tuddenham, SA Sadiq - … and neuromuscular disease, 2017 - Taylor & Francis
Multiple sclerosis (MS) is an autoimmune disease affecting the brain and spinal cord that is
associated with chronic inflammation leading to demyelination and neurodegeneration. With …
associated with chronic inflammation leading to demyelination and neurodegeneration. With …
Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment
We and others have previously demonstrated the potential for circulating exosome
microRNAs to aid in disease diagnosis. In this study, we sought the possible utility of serum …
microRNAs to aid in disease diagnosis. In this study, we sought the possible utility of serum …